* Orchid Biocomputer Inc., of Princeton, N.J., received anundisclosed milestone payment and equity investment from London-based SmithKline Beecham plc for progress in developing a high-throughput, miniaturized system of discovering drugs. Thecompany's goal is to synthesize and screen up to 10,000 compoundsagainst genetic targets on a glass chip the size of a business card.Orchid was founded in 1995 by SmithKline and the David SarnoffResearch Center.

(c) 1997 American Health Consultants. All rights reserved.